Cargando…
Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns
Multiple sclerosis (MS) is a complicated condition in which the immune system attacks myelinated axons in the central nervous system (CNS), destroying both myelin and axons to varying degrees. Several environmental, genetic, and epigenetic factors influence the risk of developing the disease and how...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146800/ https://www.ncbi.nlm.nih.gov/pubmed/37111637 http://dx.doi.org/10.3390/pharmaceutics15041151 |
_version_ | 1785034665294299136 |
---|---|
author | Nouh, Roua A. Kamal, Ahmed Abdelnaser, Anwar |
author_facet | Nouh, Roua A. Kamal, Ahmed Abdelnaser, Anwar |
author_sort | Nouh, Roua A. |
collection | PubMed |
description | Multiple sclerosis (MS) is a complicated condition in which the immune system attacks myelinated axons in the central nervous system (CNS), destroying both myelin and axons to varying degrees. Several environmental, genetic, and epigenetic factors influence the risk of developing the disease and how well it responds to treatment. Cannabinoids have recently sparked renewed interest in their therapeutic applications, with growing evidence for their role in symptom control in MS. Cannabinoids exert their roles through the endogenous cannabinoid (ECB) system, with some reports shedding light on the molecular biology of this system and lending credence to some anecdotal medical claims. The double nature of cannabinoids, which cause both positive and negative effects, comes from their actions on the same receptor. Several mechanisms have been adopted to evade this effect. However, there are still numerous limitations to using cannabinoids to treat MS patients. In this review, we will explore and discuss the molecular effect of cannabinoids on the ECB system, the various factors that affect the response to cannabinoids in the body, including the role of gene polymorphism and its relation to dosage, assessing the positive over the adverse effects of cannabinoids in MS, and finally, exploring the possible functional mechanism of cannabinoids in MS and the current and future progress of cannabinoid therapeutics. |
format | Online Article Text |
id | pubmed-10146800 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101468002023-04-29 Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns Nouh, Roua A. Kamal, Ahmed Abdelnaser, Anwar Pharmaceutics Review Multiple sclerosis (MS) is a complicated condition in which the immune system attacks myelinated axons in the central nervous system (CNS), destroying both myelin and axons to varying degrees. Several environmental, genetic, and epigenetic factors influence the risk of developing the disease and how well it responds to treatment. Cannabinoids have recently sparked renewed interest in their therapeutic applications, with growing evidence for their role in symptom control in MS. Cannabinoids exert their roles through the endogenous cannabinoid (ECB) system, with some reports shedding light on the molecular biology of this system and lending credence to some anecdotal medical claims. The double nature of cannabinoids, which cause both positive and negative effects, comes from their actions on the same receptor. Several mechanisms have been adopted to evade this effect. However, there are still numerous limitations to using cannabinoids to treat MS patients. In this review, we will explore and discuss the molecular effect of cannabinoids on the ECB system, the various factors that affect the response to cannabinoids in the body, including the role of gene polymorphism and its relation to dosage, assessing the positive over the adverse effects of cannabinoids in MS, and finally, exploring the possible functional mechanism of cannabinoids in MS and the current and future progress of cannabinoid therapeutics. MDPI 2023-04-05 /pmc/articles/PMC10146800/ /pubmed/37111637 http://dx.doi.org/10.3390/pharmaceutics15041151 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Nouh, Roua A. Kamal, Ahmed Abdelnaser, Anwar Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns |
title | Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns |
title_full | Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns |
title_fullStr | Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns |
title_full_unstemmed | Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns |
title_short | Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns |
title_sort | cannabinoids and multiple sclerosis: a critical analysis of therapeutic potentials and safety concerns |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146800/ https://www.ncbi.nlm.nih.gov/pubmed/37111637 http://dx.doi.org/10.3390/pharmaceutics15041151 |
work_keys_str_mv | AT nouhrouaa cannabinoidsandmultiplesclerosisacriticalanalysisoftherapeuticpotentialsandsafetyconcerns AT kamalahmed cannabinoidsandmultiplesclerosisacriticalanalysisoftherapeuticpotentialsandsafetyconcerns AT abdelnaseranwar cannabinoidsandmultiplesclerosisacriticalanalysisoftherapeuticpotentialsandsafetyconcerns |